Lucid Diagnostics (LUCD) to Release Quarterly Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD) is expected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Lucid Diagnostics Price Performance

Shares of LUCD opened at $1.52 on Friday. The firm has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $0.98. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.63. The stock has a market cap of $90.20 million, a PE ratio of -1.33 and a beta of 1.34.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets decreased their price target on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.